| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| RDNTRadNet, Inc. | 5.64B | 72.99 | 1951.60 | 13.18% | -0.65% | -0.97% | 0.8% | 1.53 |
| IDXXIDEXX Laboratories, Inc. | 56.86B | 712.12 | 66.74 | 6.46% | 24.65% | 65.81% | 1.4% | 0.62 |
| CDNACareDx, Inc | 1.06B | 20.57 | 22.12 | 19.07% | 16.97% | 19.53% | 2.98% | 0.07 |
| TRIBTrinity Biotech plc | 13.23M | 0.71 | -0.40 | 8.31% | -73.78% | |||
| NEOGNeogen Corporation | 2.06B | 9.46 | -1.88 | -3.2% | -68.47% | -28.64% | 0.44 | |
| STRRStar Equity Holdings, Inc. | 38.07M | 10.96 | -2.76 | -66.93% | -5.36% | -8.98% | 0.03 | |
| BGLCBioNexus Gene Lab Corp. | 8.72M | 3.69 | -4.10 | -2.66% | -24.27% | -33.7% | 0.03 | |
| NEONeoGenomics, Inc. | 1.66B | 12.83 | -4.14 | 11.65% | -16% | -13.54% | 0.67 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.65M | 1.56M | 1.72M | 2.86M | 3.13M | 6.09M | 8.85M | 9.41M | 15.2M | 15.96M |
| Revenue Growth % | -0.94% | -0.06% | 0.11% | 0.66% | 0.09% | 0.95% | 0.45% | 0.06% | 0.61% | 0.05% |
| Cost of Goods Sold | 1.94M | 1.76M | 1.43M | 2.64M | 2.91M | 4.94M | 6.46M | 6.9M | 9.18M | 8.41M |
| COGS % of Revenue | 1.17% | 1.13% | 0.83% | 0.92% | 0.93% | 0.81% | 0.73% | 0.73% | 0.6% | 0.53% |
| Gross Profit | -287K | -205K | 292K | 225K | 219K | 1.15M | 2.39M | 2.51M | 6.02M | 7.56M |
| Gross Margin % | -0.17% | -0.13% | 0.17% | 0.08% | 0.07% | 0.19% | 0.27% | 0.27% | 0.4% | 0.47% |
| Gross Profit Growth % | -1.03% | 0.29% | 2.42% | -0.23% | -0.03% | 4.25% | 1.08% | 0.05% | 1.4% | 0.26% |
| Operating Expenses | 8.91M | 7.61M | 6.49M | 9.45M | 11.21M | 10.3M | 12.01M | 15.31M | 13.64M | 11.78M |
| OpEx % of Revenue | 5.39% | 4.89% | 3.77% | 3.3% | 3.59% | 1.69% | 1.36% | 1.63% | 0.9% | 0.74% |
| Selling, General & Admin | 7.05M | 6.19M | 6.49M | 9.45M | 9.62M | 10.3M | 10.71M | 13.61M | 13.64M | 11.78M |
| SG&A % of Revenue | 4.27% | 3.98% | 3.77% | 3.3% | 3.08% | 1.69% | 1.21% | 1.45% | 0.9% | 0.74% |
| Research & Development | 1.85M | 1.42M | 500K | 1.1M | 2.79M | 2.2M | 1.3M | 1.7M | 2.7M | 2.3M |
| R&D % of Revenue | 1.12% | 0.91% | 0.29% | 0.38% | 0.89% | 0.36% | 0.15% | 0.18% | 0.18% | 0.14% |
| Other Operating Expenses | 0 | 0 | 877K | -1.33M | -1.2M | -2.2M | 0 | 0 | -2.7M | -2.3M |
| Operating Income | -9.2M | -7.82M | -15.51M | -13.91M | -10.99M | -9.15M | -9.61M | -12.8M | -7.62M | -4.22M |
| Operating Margin % | -5.56% | -5.02% | -9% | -4.86% | -3.52% | -1.5% | -1.09% | -1.36% | -0.5% | -0.26% |
| Operating Income Growth % | 0.47% | 0.15% | -0.98% | 0.1% | 0.21% | 0.17% | -0.05% | -0.33% | 0.4% | 0.45% |
| EBITDA | -8.71M | -7.71M | -14.77M | -12.65M | -9.81M | -8M | -8.17M | -11.28M | -6.31M | -2.7M |
| EBITDA Margin % | -5.27% | -4.95% | -8.57% | -4.42% | -3.14% | -1.31% | -0.92% | -1.2% | -0.42% | -0.17% |
| EBITDA Growth % | 0.42% | 0.11% | -0.92% | 0.14% | 0.22% | 0.18% | -0.02% | -0.38% | 0.44% | 0.57% |
| D&A (Non-Cash Add-back) | 489K | 112K | 743K | 1.26M | 1.18M | 1.14M | 1.44M | 1.52M | 1.31M | 1.51M |
| EBIT | -9.14M | -1.71M | -6.2M | -9.23M | -9.4M | -9.15M | -8.5M | -12.17M | -7.62M | -4.22M |
| Net Interest Income | -724K | -518K | -2.32M | -1.6M | -473K | -470K | -20K | -12K | -18K | -74K |
| Interest Income | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 724K | 518K | 2.32M | 1.6M | 473K | 470K | 20K | 12K | 18K | 74K |
| Other Income/Expense | -1.22M | -515K | -5.18M | -2.06M | -2.32M | -1.45M | 1.1M | 619K | 1.77M | -74K |
| Pretax Income | -10.14M | -8.27M | -20.69M | -15.97M | -13.31M | -10.6M | -8.52M | -12.18M | -5.85M | -4.29M |
| Pretax Margin % | -6.13% | -5.31% | -12.01% | -5.58% | -4.26% | -1.74% | -0.96% | -1.29% | -0.39% | -0.27% |
| Income Tax | 23.76M | -203K | 0 | -279K | -70K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 3.25% | 0.92% | 1% | 0.98% | 0.99% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -32.95M | -7.62M | -20.69M | -15.69M | -13.24M | -10.63M | -8.55M | -12.2M | -5.85M | -4.29M |
| Net Margin % | -19.94% | -4.89% | -12.01% | -5.48% | -4.24% | -1.74% | -0.97% | -1.3% | -0.39% | -0.27% |
| Net Income Growth % | -1.36% | 0.77% | -1.72% | 0.24% | 0.16% | 0.2% | 0.2% | -0.43% | 0.52% | 0.27% |
| Net Income (Continuing) | -9.86M | -2.23M | -20.69M | -15.69M | -13.24M | -10.6M | -8.52M | -12.18M | -5.85M | -4.29M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 27K | 40K | 65K | 0 | 0 |
| EPS (Diluted) | -870.12 | -580.93 | -1338.20 | -217.80 | -46.51 | -14.84 | -8.10 | -10.73 | -4.51 | -2.93 |
| EPS Growth % | -0.04% | 0.33% | -1.3% | 0.84% | 0.79% | 0.68% | 0.45% | -0.32% | 0.58% | 0.35% |
| EPS (Basic) | -870.12 | -580.93 | -1338.20 | -217.81 | -46.51 | -14.84 | -8.10 | -10.73 | -4.51 | -2.93 |
| Diluted Shares Outstanding | 1.37K | 48 | 15.46K | 72.06K | 284.76K | 823.85K | 1.05M | 1.14M | 1.3M | 1.47M |
| Basic Shares Outstanding | 1.37K | 48 | 15.46K | 72.06K | 284.76K | 823.85K | 1.05M | 1.14M | 1.3M | 1.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.28M | 495K | 1.74M | 1.79M | 1.88M | 4.2M | 13.48M | 5.71M | 3.68M | 3.45M |
| Cash & Short-Term Investments | 444K | 110K | 421K | 381K | 848K | 2.66M | 11.67M | 3.44M | 1.5M | 1.39M |
| Cash Only | 444K | 110K | 421K | 381K | 848K | 2.66M | 11.67M | 3.44M | 1.5M | 1.39M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 564K | 388K | 730K | 690K | 574K | 874K | 697K | 1.04M | 1.3M | 799K |
| Days Sales Outstanding | 124.54 | 90.96 | 154.64 | 87.94 | 67 | 52.37 | 28.75 | 40.18 | 31.25 | 18.27 |
| Inventory | 50K | 24K | 161K | 197K | 184K | 350K | 564K | 708K | 384K | 724K |
| Days Inventory Outstanding | 9.41 | 4.97 | 41.07 | 27.25 | 23.09 | 25.85 | 31.88 | 37.44 | 15.27 | 31.44 |
| Other Current Assets | 2.02M | 13K | 100K | 300K | 72K | 0 | 0 | 0 | 195K | 0 |
| Total Non-Current Assets | 1.53M | 764K | 25.52M | 19.81M | 17.63M | 16.51M | 16.96M | 15.79M | 14.42M | 13.54M |
| Property, Plant & Equipment | 259K | 144K | 353K | 496K | 950K | 787K | 2.06M | 1.9M | 1.52M | 1.63M |
| Fixed Asset Turnover | 6.38x | 10.81x | 4.88x | 5.77x | 3.29x | 7.74x | 4.29x | 4.96x | 9.97x | 9.79x |
| Goodwill | 0 | 0 | 4.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.17M | 562K | 20.46M | 19.29M | 16.66M | 15.67M | 14.72M | 13.77M | 12.82M | 11.87M |
| Long-Term Investments | -50K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 105K | 58K | 22K | 25K | 25K | 55K | 179K | 129K | 76K | 45K |
| Total Assets | 4.82M | 1.26M | 27.26M | 21.61M | 19.51M | 20.71M | 30.44M | 21.5M | 18.1M | 17M |
| Asset Turnover | 0.34x | 1.24x | 0.06x | 0.13x | 0.16x | 0.29x | 0.29x | 0.44x | 0.84x | 0.94x |
| Asset Growth % | -0.84% | -0.74% | 20.65% | -0.21% | -0.1% | 0.06% | 0.47% | -0.29% | -0.16% | -0.06% |
| Total Current Liabilities | 16.98M | 19.82M | 10.04M | 13.77M | 4.33M | 4.66M | 4.21M | 4.36M | 3.14M | 4.27M |
| Accounts Payable | 3.78M | 1.08M | 5.1M | 5.17M | 1.94M | 1.69M | 1.86M | 2.04M | 622K | 618K |
| Days Payables Outstanding | 711.37 | 224.55 | 1.3K | 714.92 | 243 | 125.04 | 105.31 | 107.99 | 24.73 | 26.83 |
| Short-Term Debt | 7.6M | 1.09M | 587K | 4.64M | 463K | 648K | 26K | 255K | 235K | 297K |
| Deferred Revenue (Current) | 217K | 170K | 66K | 49K | 35K | 6K | 18K | 119K | 110K | 232K |
| Other Current Liabilities | 5.03M | 92K | 4.1M | 3.73M | 1.39M | 0 | 0 | 491K | 1.04M | 955K |
| Current Ratio | 0.19x | 0.02x | 0.17x | 0.13x | 0.43x | 0.90x | 3.20x | 1.31x | 1.17x | 0.81x |
| Quick Ratio | 0.19x | 0.02x | 0.16x | 0.12x | 0.39x | 0.83x | 3.07x | 1.15x | 1.05x | 0.64x |
| Cash Conversion Cycle | -577.43 | -128.62 | -1.11K | -599.74 | -152.9 | -46.82 | -44.68 | -30.37 | 21.78 | 22.87 |
| Total Non-Current Liabilities | 655K | 785K | 4.2M | 1.72M | 1.97M | 1.9M | 1.62M | 776K | 531K | 631K |
| Long-Term Debt | 0 | 4.13M | 2.83M | 253K | 198K | 362K | 160K | 134K | 106K | 77K |
| Capital Lease Obligations | 164.19K | 163K | 113K | 155K | 436K | 208K | 856K | 642K | 425K | 554K |
| Deferred Tax Liabilities | 50K | 0 | 349K | 70K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 490.81K | 0 | 1.26M | 1.24M | 1.34M | 1.32M | 606K | 0 | 0 | 0 |
| Total Liabilities | 17.64M | 20.61M | 14.23M | 15.48M | 6.31M | 6.55M | 5.83M | 5.14M | 3.67M | 4.9M |
| Total Debt | 7.6M | 7.81M | 3.58M | 5.11M | 1.36M | 1.49M | 1.43M | 1.39M | 1.12M | 1.25M |
| Net Debt | 7.15M | 7.7M | 3.16M | 4.72M | 510K | -1.17M | -10.24M | -2.05M | -386K | -136K |
| Debt / Equity | - | - | 0.27x | 0.83x | 0.10x | 0.11x | 0.06x | 0.09x | 0.08x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -12.70x | -15.09x | -6.67x | -8.71x | -23.24x | -19.46x | -480.65x | -1066.42x | -423.33x | -56.97x |
| Total Equity | -12.82M | -19.35M | 13.03M | 6.12M | 13.21M | 14.16M | 24.6M | 16.37M | 14.43M | 12.09M |
| Equity Growth % | -2.96% | -0.51% | 1.67% | -0.53% | 1.16% | 0.07% | 0.74% | -0.33% | -0.12% | -0.16% |
| Book Value per Share | -9364.50 | -402582.63 | 842.28 | 84.98 | 46.37 | 17.19 | 23.32 | 14.39 | 11.12 | 8.25 |
| Total Shareholders' Equity | -12.82M | -19.35M | 13.03M | 6.12M | 13.21M | 14.13M | 24.56M | 16.3M | 14.43M | 12.09M |
| Common Stock | 139K | 264K | 102K | 345K | 79K | 176K | 227K | 228K | 14K | 15K |
| Retained Earnings | -213.41M | -225.49M | -31.54M | -47.7M | -60.94M | -71.56M | -80.09M | -92.3M | -98.15M | -102.44M |
| Treasury Stock | -1.72M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 10K | 0 | -555K | -653K | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 27K | 40K | 65K | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -12.38M | -3.55M | -6.69M | -6.75M | -9.14M | -7.43M | -6.58M | -7.72M | -3.56M | 439K |
| Operating CF Margin % | -7.49% | -2.28% | -3.88% | -2.36% | -2.92% | -1.22% | -0.74% | -0.82% | -0.23% | 0.03% |
| Operating CF Growth % | 0.1% | 0.71% | -0.88% | -0.01% | -0.35% | 0.19% | 0.12% | -0.17% | 0.54% | 1.12% |
| Net Income | -10.14M | -8.27M | -20.69M | -15.69M | -13.24M | -10.6M | -8.52M | -12.18M | -5.85M | -4.29M |
| Depreciation & Amortization | 489K | 262K | 743K | 1.26M | 1.41M | 1.36M | 1.44M | 1.52M | 1.52M | 1.51M |
| Stock-Based Compensation | 611K | 52K | 49K | 529K | 668K | 703K | 2.03M | 3.8M | 1.74M | 1.88M |
| Deferred Taxes | -4.38M | 1.98M | 10.69M | 5.99M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 275K | -274K | 3.7M | 1.04M | 4.51M | 2.74M | -1.14M | -221K | -1.56M | 69K |
| Working Capital Changes | 765K | 2.7M | -1.17M | 109K | -2.49M | -1.63M | -395K | -643K | 606K | 1.27M |
| Change in Receivables | 133K | -33K | -495K | -541K | -850K | -1.64M | 327K | -745K | -483K | 438K |
| Change in Inventory | -113K | 26K | -46K | -36K | 13K | -166K | -214K | -144K | 324K | -340K |
| Change in Payables | -365K | 3.08M | 500K | 309K | -1.88M | -243K | 112K | 165K | -169K | -10K |
| Cash from Investing | 1.79M | 1.01M | -42K | -97K | -55K | -96K | -682K | -277K | -126K | -223K |
| Capital Expenditures | -204K | -19K | -143K | -97K | -55K | -151K | -682K | -277K | -126K | -223K |
| CapEx % of Revenue | 0.12% | 0.01% | 0.08% | 0.03% | 0.02% | 0.02% | 0.08% | 0.03% | 0.01% | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.99M | 1.02M | 0 | 0 | 0 | 55K | 0 | 0 | 0 | 0 |
| Cash from Financing | 8.99M | 2.21M | 7.1M | 6.81M | 9.66M | 9.34M | 16.27M | -225K | 1.74M | -329K |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | -10K | 7.78M | 1.13M | 1.46M | 0 | 273K | 11K | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -12.58M | -3.57M | -6.83M | -6.85M | -9.2M | -7.58M | -7.26M | -8M | -3.69M | 216K |
| FCF Margin % | -7.61% | -2.29% | -3.97% | -2.39% | -2.94% | -1.25% | -0.82% | -0.85% | -0.24% | 0.01% |
| FCF Growth % | 0.09% | 0.72% | -0.91% | -0% | -0.34% | 0.18% | 0.04% | -0.1% | 0.54% | 1.06% |
| FCF per Share | -9190.65 | -74254.13 | -441.86 | -95.08 | -32.29 | -9.21 | -6.88 | -7.03 | -2.84 | 0.15 |
| FCF Conversion (FCF/Net Income) | 0.38x | 0.47x | 0.32x | 0.43x | 0.69x | 0.70x | 0.77x | 0.63x | 0.61x | -0.10x |
| Interest Paid | 0 | 0 | 0 | 0 | 36K | 20K | 34K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -158.88% | -163.92% | -137.03% | -77.65% | -44.11% | -59.57% | -38.01% | -32.35% |
| Return on Invested Capital (ROIC) | -207.37% | - | -512.82% | -77.2% | -67.14% | -51.36% | -52.7% | -66.93% | -40.31% | -24.32% |
| Gross Margin | -17.36% | -13.17% | 16.95% | 7.86% | 7% | 18.88% | 27.03% | 26.67% | 39.6% | 47.35% |
| Net Margin | -1993.59% | -489.15% | -1201.04% | -547.97% | -423.5% | -174.41% | -96.62% | -129.65% | -38.51% | -26.87% |
| Debt / Equity | - | - | 0.27x | 0.83x | 0.10x | 0.11x | 0.06x | 0.09x | 0.08x | 0.10x |
| Interest Coverage | -12.70x | -15.09x | -6.67x | -8.71x | -23.24x | -19.46x | -480.65x | -1066.42x | -423.33x | -56.97x |
| FCF Conversion | 0.38x | 0.47x | 0.32x | 0.43x | 0.69x | 0.70x | 0.77x | 0.63x | 0.61x | -0.10x |
| Revenue Growth | -93.9% | -5.81% | 10.66% | 66.22% | 9.18% | 94.82% | 45.26% | 6.36% | 61.46% | 5.05% |
| 2014 | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Service revenue, net | - | - | - | - | - | - | 7.93M | 8.01M | 26.49M | 39.17M |
| Service revenue, net Growth | - | - | - | - | - | - | - | 0.95% | 230.71% | 47.88% |
| Diagnostic Testing | - | - | - | - | 3.46M | 6.79M | 3.61M | 4.21M | 12.4M | 15.96M |
| Diagnostic Testing Growth | - | - | - | - | - | 96.33% | -46.76% | 16.58% | 194.37% | 28.79% |
| Biomarker Testing and Clinical Project Services | - | - | - | - | - | - | 56K | - | - | - |
| Biomarker Testing and Clinical Project Services Growth | - | - | - | - | - | - | - | - | - | - |
| Service Revenue Net | - | - | - | 3.33M | 3.08M | 5.87M | - | - | - | - |
| Service Revenue Net Growth | - | - | - | - | -7.56% | 90.46% | - | - | - | - |
| Biomarker Testing And Clinical Project Services | - | - | - | - | 595K | 426K | - | - | - | - |
| Biomarker Testing And Clinical Project Services Growth | - | - | - | - | - | -28.40% | - | - | - | - |
| Other Party | - | - | - | 113K | - | - | - | - | - | - |
| Other Party Growth | - | - | - | - | - | - | - | - | - | - |
| Clinical Research Grants | - | - | - | 100K | - | - | - | - | - | - |
| Clinical Research Grants Growth | - | - | - | - | - | - | - | - | - | - |
| Other | - | - | - | 13K | - | - | - | - | - | - |
| Other Growth | - | - | - | - | - | - | - | - | - | - |
| Pharmacogenomic services | 300K | 100K | 200K | - | - | - | - | - | - | - |
| Pharmacogenomic services Growth | - | -66.67% | 100.00% | - | - | - | - | - | - | - |
| Diagnostic tools | 700K | - | - | - | - | - | - | - | - | - |
| Diagnostic tools Growth | - | - | - | - | - | - | - | - | - | - |
| 2014 | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | 21.05M | - | - | - | - | - | - | - | - | - |
| UNITED STATES Growth | - | - | - | - | - | - | - | - | - | - |
| All Other Countries | 3.89M | - | - | - | - | - | - | - | - | - |
| All Other Countries Growth | - | - | - | - | - | - | - | - | - | - |
| ITALY | 1.26M | - | - | - | - | - | - | - | - | - |
| ITALY Growth | - | - | - | - | - | - | - | - | - | - |
Precipio, Inc. (PRPO) reported $21.5M in revenue for fiscal year 2024. This represents a 33% decrease from $32.0M in 2011.
Precipio, Inc. (PRPO) grew revenue by 5.1% over the past year. This is steady growth.
Precipio, Inc. (PRPO) reported a net loss of $1.3M for fiscal year 2024.
Precipio, Inc. (PRPO) has a return on equity (ROE) of -32.3%. Negative ROE indicates the company is unprofitable.
Precipio, Inc. (PRPO) generated $0.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.